Previous 10 | Next 10 |
Eton Pharmaceuticals ([[ETON]] +0.8%) has acquired Canadian rights to Alkindi Sprinkle from Diurnal Group.The company currently commercializes Alkindi Sprinkle in the U.S. as a replacement therapy for Adrenocortical Insufficiency in children under 17 years of age.Alkindi Sprink...
DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI®...
The FDA has accepted for review Eton Pharmaceuticals's ([[ETON]] +2.4%) marketing application seeking approval for Topiramate oral solution, for three indications, including monotherapy for treatment of partial-onset or primary general tonic-clonic seizures in patients two years age and ...
DEER PARK, Ill., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accep...
Eton Pharmaceuticals (ETON) announced the full availability of ALKINDI SPRINKLE for sale and distribution in the United States and will be available exclusively through AnovoRx, a specialty pharmacy.The FDA has approved ALKINDI SPRINKLE oral granules as replacement therapy for Adrenocort...
ALKINDI ® SPRINKLE is now exclusively available through AnovoRx Specialty Pharmacy. To support patient access to ALKINDI ® SPRINKLE, Eton has established the Eton Cares Program ® . DEER PARK, Ill., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceu...
Eton Pharmaceuticals, Inc. (ETON) Q3 2020 Earnings Conference Call November 12, 2020 16:30 ET Company Participants David Krempa - Vice President of Business Development Sean Brynjelsen - Chief Executive Officer Paul Stickler - Senior Vice President of Sales & Marketing Conference Call Par...
Eton Pharmaceuticals (ETON): Q3 GAAP EPS of -$0.31 misses by $0.06.Cash and equivalents of $7.3M and closed an equity financing which resulted in gross proceeds of ~$22.5M.Press Release For further details see: Eton Pharmaceuticals EPS misses by $0.06
DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results for the third quarter ended September...
DEER PARK, Ill., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and o...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...